StockNews.com Initiates Coverage on VolitionRx (NYSE:VNRX)

Research analysts at StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a research report issued on Tuesday. The firm set a “sell” rating on the stock.

Several other analysts have also recently issued reports on VNRX. Benchmark reiterated a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd. D. Boral Capital reiterated a “buy” rating and issued a $5.00 price objective on shares of VolitionRx in a report on Thursday, February 6th.

VolitionRx Price Performance

Shares of NYSE:VNRX opened at $0.58 on Tuesday. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.10. The firm’s 50-day moving average is $0.61 and its two-hundred day moving average is $0.65. The firm has a market capitalization of $53.86 million, a PE ratio of -1.61 and a beta of 1.20.

Insider Activity at VolitionRx

In other VolitionRx news, Director Guy Archibald Innes bought 174,764 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was acquired at an average price of $0.57 per share, for a total transaction of $99,615.48. Following the completion of the purchase, the director now owns 617,085 shares of the company’s stock, valued at approximately $351,738.45. This represents a 39.51 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Cameron John Reynolds purchased 139,811 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were bought at an average cost of $0.57 per share, for a total transaction of $79,692.27. Following the acquisition, the chief executive officer now owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. The trade was a 7.07 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 358,266 shares of company stock valued at $204,212 in the last three months. 12.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On VolitionRx

A number of large investors have recently bought and sold shares of the company. Millennium Management LLC acquired a new position in shares of VolitionRx during the fourth quarter worth about $36,000. Lagoda Investment Management L.P. increased its stake in VolitionRx by 24.3% in the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. Northern Trust Corp increased its position in shares of VolitionRx by 32.0% in the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after buying an additional 28,579 shares in the last quarter. Two Sigma Securities LLC acquired a new position in VolitionRx during the fourth quarter worth about $29,000. Finally, Geode Capital Management LLC lifted its holdings in shares of VolitionRx by 15.1% in the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after purchasing an additional 95,900 shares in the last quarter. Hedge funds and other institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.